{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:49:56Z","timestamp":1791910196638,"version":"4.3.4"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021281","name":"Gates Foundation","doi-asserted-by":"publisher","award":["INV-006096"],"award-info":[{"award-number":["INV-006096"]}],"id":[{"id":"10.13039\/100021281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberculosis-preventive treatment (TPT) is recommended for those at risk of tuberculosis, but despite encouraging trial data, evidence of its effectiveness from routine settings with diverse TPT regimens is limited. We describe routine TPT implementation outcomes in people living with human immunodeficiency virus (HIV; PLWH) to identify bottlenecks and opportunities for improvement along the cascade of care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From 2021\u20132023, we conducted a 24-month prospective cohort study of PLWH facilities in Ethiopia, South Africa and Zimbabwe. Sociodemographic and clinical data were collected at enrollment. During follow-up, we collected TPT initiation, TPT-related adverse effects, and completion data. A subgroup was allocated digital boxes as a proxy measure for assessing treatment completion. Tuberculosis diagnoses were confirmed from clinic records or symptom agnostic sputum testing using Xpert MTB\/RIF assay and mycobacteria growth indicator tube (MGIT) culture at 12- and 24 months after enrollment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We enrolled 2095 participants, mostly female (n = 1489 [71.1%]), with a median age of 42 years (interquartile range, 35\u201350 years). Approximately 60% (n = 1312) were considered eligible for TPT, and 1110 (84.6%) initiated TPT within 60 days of antiretroviral therapy initiation or refill during follow-up (rifapentine and isoniazid [3HP] in 625 and 6 or 12 months of isoniazid [6H\/12H] in 487). TPT was completed in 55.4% (406 of 733). Mild symptoms compatible with TPT adverse effects were commonly reported in 3HP versus 6H\/12H (190 [31.0%] vs 51 [11.0%], respectively; P &amp;lt; .001]. The tuberculosis incidence rate was 1.27\/100 person-years (95% confidence interval, .95\u20131.69) during study follow-up in a mostly long-term antiretroviral therapy population and was lower for PLWH who completed TPT (adjusted incidence rate ratio, 0.39 [.20\u2013.78]; P = .01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There were losses along the cascade, particularly at completion. In programmatic settings, we observed more potential mild symptoms from 3HP compared to 6H\/12H use. Interventions to support TPT completion are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag595","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:35:00Z","timestamp":1789673700000},"source":"Crossref","is-referenced-by-count":0,"title":["High Initiation but Suboptimal Completion of Tuberculosis-Preventive Treatment Among People Living With HIV on Antiretroviral Therapy, Persistent Tuberculosis Incidence, and Programmatic Implications: Findings From a 2-Year Multicountry Cohort Study"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0083-8319","authenticated-orcid":false,"given":"L","family":"Chimoyi","sequence":"first","affiliation":[{"name":"Implementation Research Division, The Aurum Institute , Isando ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Ginindza","sequence":"additional","affiliation":[{"name":"Implementation Research Division, The Aurum Institute , Isando ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5633-7487","authenticated-orcid":false,"given":"B A S","family":"Nonyane","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2628-7460","authenticated-orcid":false,"given":"C","family":"Mulder","sequence":"additional","affiliation":[{"name":"Department of TB Elimination and Health System Innovations, KNCV Tuberculosis Plus , The Hague ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Bedru","sequence":"additional","affiliation":[{"name":"KNCV Tuberculosis Plus , Addis Ababa ,","place":["Ethiopia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Kawaza","sequence":"additional","affiliation":[{"name":"TB\/HIV Department, Clinton Health Access Initiative , Harare ,","place":["Zimbabwe"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2398-3145","authenticated-orcid":false,"given":"J E","family":"Golub","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2049-4258","authenticated-orcid":false,"given":"K","family":"Shearer","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7148-9773","authenticated-orcid":false,"given":"A","family":"Kennar","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Mvusi","sequence":"additional","affiliation":[{"name":"TB Cluster, National Department of Health , Pretoria ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Vilakazi-Nhlapo","sequence":"additional","affiliation":[{"name":"TB Cluster, National Department of Health , Pretoria ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Apollo","sequence":"additional","affiliation":[{"name":"National TB and Leprosy Program, Ministry of Health and Child Care , Harare ,","place":["Zimbabwe"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ncube","sequence":"additional","affiliation":[{"name":"National TB and Leprosy Program, Ministry of Health and Child Care , Harare ,","place":["Zimbabwe"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Gwanzura","sequence":"additional","affiliation":[{"name":"National TB and Leprosy Program, Ministry of Health and Child Care , Harare ,","place":["Zimbabwe"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Bisa","sequence":"additional","affiliation":[{"name":"Addis Ababa Health Bureau , Addis Ababa ,","place":["Ethiopia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Gadissa","sequence":"additional","affiliation":[{"name":"KNCV Tuberculosis Plus , Addis Ababa ,","place":["Ethiopia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Mabuto","sequence":"additional","affiliation":[{"name":"Implementation Research Division, The Aurum Institute , Isando ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Tsope","sequence":"additional","affiliation":[{"name":"Implementation Research Division, The Aurum Institute , Isando ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Rabothata","sequence":"additional","affiliation":[{"name":"Implementation Research Division, The Aurum Institute , Isando ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0285-5163","authenticated-orcid":false,"given":"N","family":"Ntombela","sequence":"additional","affiliation":[{"name":"Implementation Research Division, The Aurum Institute , Isando ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Sithole","sequence":"additional","affiliation":[{"name":"TB\/HIV Department, Clinton Health Access Initiative , Harare ,","place":["Zimbabwe"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1965-2837","authenticated-orcid":false,"given":"S","family":"Sisay","sequence":"additional","affiliation":[{"name":"KNCV Tuberculosis Plus , Addis Ababa ,","place":["Ethiopia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Makgabo","sequence":"additional","affiliation":[{"name":"Implementation Research Division, The Aurum Institute , Isando ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4710-925X","authenticated-orcid":false,"given":"R E","family":"Chaisson","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4269-3699","authenticated-orcid":false,"given":"G","family":"Churchyard","sequence":"additional","affiliation":[{"name":"Implementation Research Division, The Aurum Institute , Isando ,","place":["South Africa"]},{"name":"School of Public Health, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]},{"name":"Department of Medicine, Division of Infectious Diseases, Vanderbilt University , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9422-0519","authenticated-orcid":false,"given":"C J","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Implementation Research Division, The Aurum Institute , Isando ,","place":["South Africa"]},{"name":"Center for Tuberculosis Research, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1444-9266","authenticated-orcid":false,"given":"V","family":"Chihota","sequence":"additional","affiliation":[{"name":"Implementation Research Division, The Aurum Institute , Isando ,","place":["South Africa"]},{"name":"School of Public Health, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]},{"name":"Department of Medicine, Division of Infectious Diseases, Vanderbilt University , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"2026101312102780200_ofag595-B1","volume-title":"Global tuberculosis report 2024","author":"World Health Organization","year":"2024"},{"key":"2026101312102780200_ofag595-B2","volume-title":"Policy statement on preventive therapy against tuberculosis in people living with HIV","author":"Godfrey-Faussett","year":"1998"},{"key":"2026101312102780200_ofag595-B3","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1507198","article-title":"A trial of early antiretrovirals and isoniazid preventive therapy in Africa","volume":"373","author":"Danel","year":"2015","journal-title":"N Engl J Med"},{"key":"2026101312102780200_ofag595-B4","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(15)60570-0","article-title":"WHO's new end TB strategy","volume":"385","author":"Uplekar","year":"2015","journal-title":"Lancet"},{"key":"2026101312102780200_ofag595-B5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.5588\/ijtld.21.0293","article-title":"TB preventive treatment in high-and intermediate-incidence countries: research needs for scale-up","volume":"25","author":"Oxlade","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026101312102780200_ofag595-B6","volume-title":"Guidelines on the management of tuberculosis in people living with HIV","author":"World Health Organization","year":"2021"},{"key":"2026101312102780200_ofag595-B7","volume-title":"National consolidated guidelines for the management of HIV in adults, adolescents, children and infants and prevention of mother-to-child-transmission","author":"National Department of Health","year":"2023"},{"key":"2026101312102780200_ofag595-B8","volume-title":"Guidelines for HIV prevention, testing and treatment of HIV in Zimbabwe","author":"Ministry of Health and Child Care","year":"2022"},{"key":"2026101312102780200_ofag595-B9","volume-title":"National consolidated guidelines for comprehensive HIV prevention, care and treatment","author":"Federal Ministry of Health","year":"2018"},{"key":"2026101312102780200_ofag595-B10","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.7326\/M20-7577","article-title":"Annual tuberculosis preventive therapy for persons with HIV infection: a randomized trial","volume":"174","author":"Churchyard","year":"2021","journal-title":"Ann Intern Med"},{"key":"2026101312102780200_ofag595-B11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365","author":"Martinson","year":"2011","journal-title":"N Engl J Med"},{"key":"2026101312102780200_ofag595-B12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003875","article-title":"Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: interim analysis of a hybrid type 3 effectiveness-implementation randomized trial","volume":"18","author":"Semitala","year":"2021","journal-title":"PLoS Med"},{"key":"2026101312102780200_ofag595-B13","volume-title":"WHO Operational handbook on tuberculosis. Module 1: prevention\u2014tuberculosis preventive treatment","author":"World Health Organization","year":"2020"},{"key":"2026101312102780200_ofag595-B14","doi-asserted-by":"crossref","DOI":"10.2471\/B09471","volume-title":"Overview of WHO recommendations on HIV and sexually transmitted infection testing, prevention, treatment, care and service delivery","author":"World Health Organization","year":"2025"},{"key":"2026101312102780200_ofag595-B15","volume-title":"Effectiveness of 3HP annually vs once for HIV-positive people: the WHIP3TB trial","author":"Churchyard","year":"2020"},{"key":"2026101312102780200_ofag595-B16","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","article-title":"Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons","volume":"30","author":"Sterling","year":"2016","journal-title":"AIDS"},{"key":"2026101312102780200_ofag595-B17","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2026101312102780200_ofag595-B18","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"2026101312102780200_ofag595-B19","volume-title":"Stata Statistical Software. Release 18","author":"StataCorp","year":"2019"},{"key":"2026101312102780200_ofag595-B20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2024-018469","article-title":"The implementation of tuberculosis preventive therapy in HIV care clinics in Africa, Asia and Latin America: a multiregional site survey","volume":"11","author":"Schmutz","year":"2026","journal-title":"BMJ Glob Health"},{"key":"2026101312102780200_ofag595-B21","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26105","article-title":"Integrating 3HP-based tuberculosis preventive treatment into Zimbabwe's Fast Track HIV treatment model: experiences from a pilot study","volume":"26","author":"Mapingure","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"2026101312102780200_ofag595-B22","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1186\/s12889-020-09902-z","article-title":"Evaluation of the uptake of tuberculosis preventative therapy for people living with HIV in Namibia: a multiple methods analysis","volume":"20","author":"Roscoe","year":"2020","journal-title":"BMC Public Health"},{"key":"2026101312102780200_ofag595-B23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004356","article-title":"Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: a single-center randomized trial","volume":"21","author":"Semitala","year":"2024","journal-title":"PLoS Med"},{"key":"2026101312102780200_ofag595-B24","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(23)00096-6","article-title":"Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis","volume":"11","author":"Winters","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026101312102780200_ofag595-B25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003703","article-title":"The latent tuberculosis cascade-of-care among people living with HIV: a systematic review and meta-analysis","volume":"18","author":"Bastos","year":"2021","journal-title":"PLoS Med"},{"key":"2026101312102780200_ofag595-B26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"2026101312102780200_ofag595-B27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/cid\/ciad246","article-title":"A systematic review and meta-analysis of tuberculous preventative therapy adverse events","volume":"77","author":"Melnychuk","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026101312102780200_ofag595-B28","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2023.107173","article-title":"Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine","volume":"129","author":"Scott","year":"2023","journal-title":"Contemp Clin Trials"},{"key":"2026101312102780200_ofag595-B29","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/tmi.13940","article-title":"Implementation of tuberculosis preventive therapy with INH-rifapentine (3HP) for latent tuberculosis infection management in household tuberculosis contacts in India: a prospective study","volume":"28","author":"Sharma","year":"2023","journal-title":"Trop Med Int Health"},{"key":"2026101312102780200_ofag595-B30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0001920","article-title":"Community-based tuberculosis contact management: caregiver experience and factors promoting adherence to preventive therapy","volume":"3","author":"Sandoval","year":"2023","journal-title":"PLoS Glob Public Health"},{"key":"2026101312102780200_ofag595-B31","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","article-title":"The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis","volume":"16","author":"Alsdurf","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026101312102780200_ofag595-B32","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1186\/s12889-025-23090-8","article-title":"Incidence and risk factors for tuberculosis at a rural HIV clinic in Uganda, 2012\u20132019: a retrospective cohort study","volume":"25","author":"Sendagire","year":"2025","journal-title":"BMC Public Health"},{"key":"2026101312102780200_ofag595-B33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001270","article-title":"Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis","volume":"9","author":"Suthar","year":"2012","journal-title":"PLoS Med"},{"key":"2026101312102780200_ofag595-B34","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/cid\/ciac185","article-title":"Recurrent subclinical tuberculosis among antiretroviral therapy-accessing participants: incidence, clinical course, and outcomes","volume":"75","author":"Naidoo","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026101312102780200_ofag595-B35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12879-018-3614-7","article-title":"Subclinical tuberculosis among adults with HIV: clinical features and outcomes in a South African cohort","volume":"19","author":"Bajema","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2026101312102780200_ofag595-B36","doi-asserted-by":"crossref","first-page":"e830","DOI":"10.1093\/cid\/ciaa1402","article-title":"Subclinical tuberculosis disease\u2014a review and analysis of prevalence surveys to inform definitions, burden, associations, and screening methodology","volume":"73","author":"Frascella","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026101312102780200_ofag595-B37","doi-asserted-by":"crossref","first-page":"230208","DOI":"10.1183\/16000617.0208-2023","article-title":"Subclinical tuberculosis: a meta-analysis of prevalence and scoping review of definitions, prevalence and clinical characteristics","volume":"33","author":"Teo","year":"2024","journal-title":"Eur Respir Rev"},{"key":"2026101312102780200_ofag595-B38","volume-title":"The urgency of now: AIDS at a crossroads","author":"Joint United Nations Programme on HIV\/AIDS","year":"2024"},{"key":"2026101312102780200_ofag595-B39","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s10461-019-02603-8","article-title":"Gender norms and HIV testing\/treatment uptake: evidence from a large population-based sample in South Africa","volume":"23","author":"Pulerwitz","year":"2019","journal-title":"AIDS Behav"},{"key":"2026101312102780200_ofag595-B40","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1186\/s12889-020-09660-y","article-title":"Women's healthcare decision-making capacity and HIV testing in sub-Saharan Africa: a multi-country analysis of demographic and health surveys","volume":"20","author":"Seidu","year":"2020","journal-title":"BMC Public Health"},{"key":"2026101312102780200_ofag595-B41","volume-title":"Demographic patterns of HIV testing uptake in sub-Saharan Africa","author":"Staveteig","year":"2013"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/10\/ofag595\/71914084\/ofag595.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/10\/ofag595\/71914084\/ofag595.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:10:40Z","timestamp":1791907840000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag595\/8914512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag595","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,29]]},"article-number":"ofag595"}}